Kaissan (Clopidogrel Hydrochloride)

Clopidogrel is a pro‑drug that is converted in the liver to an active metabolite. This metabolite binds irreversibly to the platelet P2Y12 ADP receptor, blocking ADP‑mediated activation of the GPIIb/IIIa complex and preventing platelet aggregation, which reduces clot formation in arteries.

The appropriate dose of Kaissan is determined by the prescribing clinician based on the individual patient's medical condition, risk factors, and concomitant therapies. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of clopidogrel during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kaissan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kaissan (clopidogrel) is a P2Y12 receptor antagonist, whereas alternatives like aspirin inhibit cyclo‑oxygenase‑1. Clopidogrel provides more consistent platelet inhibition in patients who are aspirin‑resistant or require dual antiplatelet therapy, but it may have a higher cost and different interaction profile.

Kaissan should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in a humid environment or expose the tablets to excessive heat.

Kaissan is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

The most serious risks include severe or life‑threatening bleeding, such as gastrointestinal or intracranial hemorrhage, and rare blood disorders like thrombocytopenia. Patients should seek immediate medical attention if they experience unusual bruising, bleeding, or signs of an allergic reaction.

Kaissan should not be used by patients with active pathological bleeding, severe liver disease, or known hypersensitivity to clopidogrel or any of its components. It is also contraindicated in individuals who have had a recent major surgery unless advised otherwise by a physician.